S Bank Fund Management Ltd Makes New Investment in Pfizer Inc. (NYSE:PFE)

Key Points

• S Bank Fund Management Ltd has acquired 39,145 shares of Pfizer Inc., valued at approximately $992,000, marking a new position for the fund.
• Pfizer's stock recently opened at $24.64 with a market capitalization of $140.06 billion, and it posted quarterly earnings of $0.78 per share, exceeding expectations.
• The company has announced a quarterly dividend of $0.43 per share, reflecting a significant annual yield of 7.0%.

S Bank Fund Management Ltd purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 39,145 shares of the biopharmaceutical company's stock, valued at approximately $992,000.

A number of other institutional investors also recently bought and sold shares of PFE. Clarity Asset Management Inc. acquired a new position in Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $24.64 on Wednesday. The company has a market capitalization of $140.06 billion, a PE ratio of 13.10, a P/E/G ratio of 0.88 and a beta of 0.52. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a 50 day simple moving average of $24.49 and a two-hundred day simple moving average of $24.47. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. BMO Capital Markets cut their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. TD Cowen lowered their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.